RFK Jr. removes all members of CDC panel advising U.S. on vaccines

RFK Jr. removes all members of CDC panel advising U.S. on vaccines


U.S. Health and Human Services (HHS) Secretary Robert F. Kennedy Jr. testifies before the Senate Committee on Appropriations hearing on the Department of Health and Human Services budget, on Capitol Hill in Washington, D.C., U.S., May 20, 2025.

Ken Cedeno | Reuters

Health and Human Services Secretary Robert F. Kennedy Jr. on Monday said he is “retiring” all 17 members of a crucial government panel of vaccine advisors, a shocking step that could help to sow doubts about immunizations in the U.S.

“A clean sweep is needed to re-establish public confidence in vaccine science,” Kennedy said in an opinion piece in the Wall Street Journal on Monday.

Kennedy is removing all members of the Advisory Committee on Immunization Practices, or ACIP, which advises the Centers for Disease Control and Prevention. The group reviews vaccine data and makes recommendations that determine who is eligible for shots and whether insurers should cover them, among other efforts.

ACIP members are independent medical and public experts who make recommendations based on rigorous scientific review and evidence. The CDC director has to sign off on those recommendations for them to become official policy.

It is unclear who Kennedy will appoint to the new group. In a release, HHS said ACIP will still hold a planned meeting from June 25 to 27 to make recommendations.

The advisor overhaul is the latest move by Kennedy – a prominent vaccine skeptic – to change and potentially undermine vaccinations in the U.S. since he took the helm at HHS. Under Kennedy, HHS stopped recommending routine Covid-19 vaccines for healthy children and healthy pregnant women and canceled programs intended to discover new vaccines to prevent future pandemics, among other changes.

Kennedy said Monday HHS will put “the restoration of public trust above any pro- or antivaccine agenda.”

Kennedy added some of the members on the committee were last-minute appointees of the Biden administration and noted that, without ousting advisors from the current group, the Trump administration would not have been able to appoint a majority of new members until 2028.

Kennedy claimed that the panel has been “plagued with persistent conflicts of interest and has become little more than a rubber stamp for any vaccine.”

But all HHS agencies and their advisory panels have had rigorous policies for conflicts of interest, and there have been no related issues for years. All members of federal vaccine advisory committees are already required to comply with regulations around disclosing potential conflicts of interest.

The announcement comes days after pediatric infectious disease expert Dr. Lakshmi Panagiotakopoulos resigned as co-leader of ACIP due to the belief she is “no longer able to help the most vulnerable members” of the U.S. population.

Late last month, Kennedy said HHS will stop recommending routine Covid-19 vaccines for healthy children and healthy pregnant women, sparking a wave of outrage in the scientific and medical world.

Health policy experts previously told CNBC that a shake-up of the advisory committee could produce politicized recommendations that highlight the harms rather than the benefits of shots. Those recommendations could also create greater distrust in the CDC and Trump administration among scientists and public health experts.

This is breaking news. Please refresh for updates.



Source

Another alliance of health care and AI signals why pharma stocks should be back in favor
Health

Another alliance of health care and AI signals why pharma stocks should be back in favor

Bristol Myers Squibb and Microsoft ‘s new partnership aimed at accelerating early detection of lung cancer marks the latest way health care and artificial intelligence are rapidly intersecting. Bristol Myers said on Tuesday it will work with Microsoft’s AI-powered radiology platform to develop and launch imaging algorithms. These new tools, which can be used to […]

Read More
Drug pricing, patent losses and deals: Here’s what pharma execs see ahead in the industry
Health

Drug pricing, patent losses and deals: Here’s what pharma execs see ahead in the industry

US President Donald Trump arrives for an announcement in the Roosevelt Room of the White House in Washington, DC, US, on Friday, Dec. 19, 2025. Will Oliver | Bloomberg | Getty Images Drug pricing. Looming patent cliffs. Dealmaking. The first year of Trump 2.0. Those are among the themes that dominated conversations last week as drugmakers […]

Read More
Making U.S. biotech more competitive with China’s could help rare disease patients, experts say
Health

Making U.S. biotech more competitive with China’s could help rare disease patients, experts say

The growth of China’s biotechnology sector has been staggering. Beijing is pumping money into the industry, backing research efforts and helping launch a new wave of labs and incubators in the country. That’s a problem for the U.S. biotech industry and also affects rare disease patients who are waiting for a cure. Among the experts […]

Read More